MBX Biosciences provides update on clinical programs

MBX Biosciences (MBX) announced it will provide an update on its clinical programs, expanding obesity pipeline, and outlook for 2026 during the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Key highlights: One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026; 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026; Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, each designed for once-monthly dosing